Better biopharma IB vertical- WF or SVB Leerink?
Both have expanded a ton in healthcare last year. WF is on a hiring spree and SVB just poached a bunch of MDs from BB. Overall, WF generates bigger fees however has mostly led via balance sheets SVB has a bigger presence in biotech IPOs and more recently M&A however it is still much small resource wise than WF.
Which will have the better healthcare group in 2022 and beyond?
SVBL - just looked and they’ve already closed 6 M&A deals YTD. They closed 18 in 2021 and 12 in 2020. Clearly making an increased effort to have a presence in the M&A space.
Yeah, the Zogenix UCB one was huge. Where do you find a full list of M&A activity?
I checked their site and filtered by m&a
Think of it this way, if you have an interest in biopharma being, at SVBL will get you looks from any other healthcare shop on the street if you decide to lateral. Leerink seems to be continuing upon and executing their efforts to take a larger share of the M&A pool. Get yourself on Dan Dubin's team and you'll be gucci
Didn't realize Dan Dubin is a Harvard trained dermatologist on Wall Street. That's incredible and no wonder SVBL does well in biopharma when their head MD is an actual M.D.
Iure repellendus voluptatem doloribus sunt nemo iste consequatur. Fugiat sit et esse explicabo nisi. Iure perspiciatis ullam voluptate. Corrupti facilis ea sit facere aliquid.
Sapiente aut ea rerum eum rerum. Qui soluta enim id tempora. Quasi quia neque pariatur officia voluptatem.
Consequuntur aperiam sunt architecto omnis at. Tempora ut ut omnis pariatur. Laborum et ratione perspiciatis quam rerum omnis. Magni ut sed accusamus minus sunt.
Odit tempora facilis quia quod. Aut expedita nobis ab odit commodi autem. Non repudiandae architecto non enim tempora quo.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...